Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Urologix v. ProstaLund

This article was originally published in The Gray Sheet

Executive Summary

Motion for preliminary injunction against sales of ProstaLund's CoreTherm microwave thermotherapy system for benign prostatic hyperplasia is denied by Milwaukee federal court Judge Lynn Adelman, clearing the way for U.S. marketing, pending PMA approval "in the near future," ProstaLund says. Adelman also rules that one of two Urologix patents asserted against ProstaLund is invalid. ACMI will distribute the device...

You may also be interested in...

ProstaLund CoreTherm BPH Device Arrives In U.S., Distributed Through ACMI

ProstaLund will immediately fill $2.3 mil. in back-orders for its CoreTherm microwave transurethral benign prostatic hyperplasia (BPH) treatment device, approved via PMA in December

Aducanumab Review: Looking For Precedents – Long Ago And Far Afield

The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.

The Rebate Rule May Not Last, But It Changed The Pricing Debate

Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts